MacroGenics, Inc. announced on October 22, 2024, that it has entered into an agreement with TerSera Therapeutics LLC for the sale of global rights to MARGENZA (margetuximab-cmkb). This transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Under the terms of the agreement, MacroGenics will receive an upfront payment of $40 million at closing. The company also stands to receive additional sales milestone payments of up to an aggregate of $35 million, providing further non-dilutive capital.
This divestiture enables MacroGenics to concentrate its efforts and resources on advancing its pipeline of novel and differentiated oncology product candidates. The deal leverages TerSera’s established commercial infrastructure to potentially broaden patient access to MARGENZA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.